CA2983151C - Compositions and methods for neuroprotection and treatment of neurodegeneration - Google Patents

Compositions and methods for neuroprotection and treatment of neurodegeneration Download PDF

Info

Publication number
CA2983151C
CA2983151C CA2983151A CA2983151A CA2983151C CA 2983151 C CA2983151 C CA 2983151C CA 2983151 A CA2983151 A CA 2983151A CA 2983151 A CA2983151 A CA 2983151A CA 2983151 C CA2983151 C CA 2983151C
Authority
CA
Canada
Prior art keywords
creatine
administration
effective amount
composition
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2983151A
Other languages
English (en)
French (fr)
Other versions
CA2983151A1 (en
Inventor
Mark C. Faulkner
Donald W. Miller
Grant M. Hatch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vireo Systems Inc
Original Assignee
Vireo Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vireo Systems Inc filed Critical Vireo Systems Inc
Publication of CA2983151A1 publication Critical patent/CA2983151A1/en
Application granted granted Critical
Publication of CA2983151C publication Critical patent/CA2983151C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2983151A 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration Active CA2983151C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562150113P 2015-04-20 2015-04-20
US62/150,113 2015-04-20
US15/133,501 US10245245B2 (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration
US15/133,501 2016-04-20
PCT/US2016/028357 WO2016172148A1 (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration

Publications (2)

Publication Number Publication Date
CA2983151A1 CA2983151A1 (en) 2016-10-27
CA2983151C true CA2983151C (en) 2024-03-05

Family

ID=57128180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2983151A Active CA2983151C (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration

Country Status (7)

Country Link
US (3) US10245245B2 (https=)
EP (1) EP3285755B1 (https=)
JP (2) JP6882191B2 (https=)
CA (1) CA2983151C (https=)
ES (1) ES2903136T3 (https=)
PL (1) PL3285755T3 (https=)
WO (1) WO2016172148A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3285755T3 (pl) 2015-04-20 2022-02-21 Vireo Systems, Inc. Chlorowodorek kreatyny do leczenia choroby Huntingtona
US11154499B2 (en) 2018-03-27 2021-10-26 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
CA3095440A1 (en) * 2018-03-27 2019-10-03 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
WO2020264412A1 (en) * 2019-06-28 2020-12-30 Thermolife International, Llc Compositions for creatine supplementation in creatine non-responders
WO2022109465A1 (en) 2020-11-23 2022-05-27 Vireo Systems, Inc. Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4151996A (en) 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
WO2002069740A1 (en) * 2001-03-02 2002-09-12 The Howard Foundation Compositions containing creatine and creatinine
US7608641B2 (en) 2003-05-15 2009-10-27 Board Of Regents Of The University Of Nebraska Creatine oral supplementation using creatine hydrochloride salt
US8354450B2 (en) * 2003-05-15 2013-01-15 Vireo Systems, Inc. Creatine oral supplementation using creatine hydrochloride salt
JP2008544254A (ja) 2005-06-13 2008-12-04 ストラタジーン カリフォルニア 別個の光学経路を有している蛍光の励起および検出のためのシステムおよび方法
EP2468272A1 (en) * 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
AU2008261094B2 (en) * 2007-06-05 2014-07-17 Cryxa Llc Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
US8445466B2 (en) * 2010-04-08 2013-05-21 John H. Owoc Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
US20150164847A1 (en) * 2013-12-16 2015-06-18 Vireo Systems, Inc. Method and composition for treating osteoarthritis
PL3285755T3 (pl) * 2015-04-20 2022-02-21 Vireo Systems, Inc. Chlorowodorek kreatyny do leczenia choroby Huntingtona

Also Published As

Publication number Publication date
JP2021120388A (ja) 2021-08-19
US20190224151A1 (en) 2019-07-25
JP2018513204A (ja) 2018-05-24
WO2016172148A1 (en) 2016-10-27
EP3285755B1 (en) 2021-10-13
US20160303061A1 (en) 2016-10-20
PL3285755T3 (pl) 2022-02-21
ES2903136T3 (es) 2022-03-31
CA2983151A1 (en) 2016-10-27
US10583105B2 (en) 2020-03-10
US10245245B2 (en) 2019-04-02
US11160776B2 (en) 2021-11-02
EP3285755A4 (en) 2018-12-05
JP6882191B2 (ja) 2021-06-02
US20200316000A1 (en) 2020-10-08
EP3285755A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
US11160776B2 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
ES2959111T3 (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de Nrf2
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
JP2023040211A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
CN106604725A (zh) 治疗肥胖症，防止体重增加，促进体重减轻，促进减肥，或治疗或预防糖尿病的发展的方法和组合物
CN116546960A (zh) 衰老细胞裂解化合物和组合物
KR20180048707A (ko) 중환자 치료 동안 사용을 위한 진정제 및 비경구 제제의 방법들
JP2010522146A (ja) タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用
US20130084334A1 (en) Pharmaceutical compositions highly dosed with biotin
TW202126294A (zh) 小分子PI4KIIIα抑制劑組合物、其製備方法及用途
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
EP3217984B1 (en) Caffeine for the treatment of myotonic dystrophy type 1 and type 2
CN113993842B (zh) 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途
US20220008388A1 (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
WO2022157798A1 (en) Synergistic nutritional compositions for treating neurocognitive disorders
US20220233484A1 (en) Synergistic nutritional compositions for treating neurocognitive disorders
KR20010040671A (ko) 소뇌 기능장애 예방 또는 치료를 위한2-아미노-6-트리플루오로메톡시-벤조티아졸의 용도
WO2018167162A1 (en) Therapeutic dosage and regimen for melatonin
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
EP4705274A1 (en) Modified forms of ambroxol for therapeutic use
HK40074190B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
ES2326355A1 (es) Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
HK1236838B (zh) 治疗肥胖症，防止体重增加，促进体重减轻或治疗或预防糖尿病的发展的方法和组合物
HK1209335B (en) Baclofen and acamprosate based therapy of macular degeneration disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210419

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250319

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250319

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260225